Afzal Elaheh, Pakzad Mohammad, Nouri Masoumeh, Moghadasali Reza, Zarrabi Morteza
Research and Development Department, Royan Stem Cell Technology Company, Cord Blood Bank, Tehran, Iran.
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Cell Tissue Bank. 2023 Mar;24(1):59-66. doi: 10.1007/s10561-022-10011-x. Epub 2022 May 30.
In the use of bovine fetal serum (FBS) there is concern about the possibility of disease transmission from animal to human. Therefore, it seems necessary to create culture conditions free of animal serum, especially in cell therapy. The aim of this study was to evaluate the feasibility of replacing human umbilical cord serum (hUCS) with FBS for in vitro expansion of umbilical cord mesenchymal stromal/stem cells (UC-MSCs). Here, UC-MSCs were cultured for five days in media supplemented either by hUCS or commercial FBS (Gibco and HyClone) to compare their viability, proliferation, morphology, Immunophenotype and differentiation potential. Our data shows that use of 5% and/or 10% hUCS, resulted in a tenfold increase in the number of MSCs; While in the presence of commercial FBS, this figure reached a maximum of five times. Notably, the rate of cell proliferation in the group containing 2% hUCS was the same as the groups containing 10% commercial FBS. Furthermore, there was no significant difference between groups in terms of viability, surface markers, and multilineage differentiation potential. These results demonstrated that hUCS can efficiently replace FBS for the routine culture of MSCs and can be used ideally in manufacturing process of UC-MSCs in cell therapy industry.
在使用牛胎血清(FBS)时,人们担心存在从动物传播疾病给人类的可能性。因此,创建无动物血清的培养条件似乎很有必要,尤其是在细胞治疗中。本研究的目的是评估用人脐带血清(hUCS)替代FBS用于脐带间充质基质/干细胞(UC-MSCs)体外扩增的可行性。在此,将UC-MSCs在补充有hUCS或商业FBS(Gibco和HyClone)的培养基中培养五天,以比较它们的活力、增殖、形态、免疫表型和分化潜能。我们的数据表明,使用5%和/或10%的hUCS可使间充质干细胞数量增加十倍;而在商业FBS存在的情况下,这一数字最多达到五倍。值得注意的是,含有2% hUCS的组中的细胞增殖速率与含有10%商业FBS的组相同。此外,各组在活力、表面标志物和多谱系分化潜能方面没有显著差异。这些结果表明,hUCS可以有效地替代FBS用于间充质干细胞的常规培养,并可理想地用于细胞治疗行业中UC-MSCs的制造过程。